Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells $301,020.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 6,000 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $50.17, for a total value of $301,020.00. Following the transaction, the general counsel now owns 45,634 shares in the company, valued at approximately $2,289,457.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Revolution Medicines Price Performance

RVMD stock opened at $50.42 on Thursday. The business has a 50 day simple moving average of $44.51 and a 200-day simple moving average of $41.09. The firm has a market capitalization of $8.42 billion, a PE ratio of -13.85 and a beta of 1.43. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $51.00.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. During the same quarter in the previous year, the company earned ($0.92) EPS. The business’s revenue was down 73.8% compared to the same quarter last year. On average, equities research analysts expect that Revolution Medicines, Inc. will post -3.35 EPS for the current year.

Wall Street Analyst Weigh In

RVMD has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $56.00 price target on shares of Revolution Medicines in a research report on Monday, August 12th. Barclays upped their price objective on Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, September 27th. JPMorgan Chase & Co. cut their price target on Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $61.00 price target on shares of Revolution Medicines in a report on Monday, October 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and a consensus price target of $54.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RVMD. GAMMA Investing LLC raised its stake in shares of Revolution Medicines by 55.8% in the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after acquiring an additional 222 shares in the last quarter. Headlands Technologies LLC grew its holdings in shares of Revolution Medicines by 140.9% during the first quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock worth $49,000 after buying an additional 885 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Revolution Medicines during the first quarter worth about $104,000. EntryPoint Capital LLC purchased a new position in shares of Revolution Medicines during the first quarter worth about $107,000. Finally, Nisa Investment Advisors LLC lifted its position in Revolution Medicines by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after purchasing an additional 320 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.